Experienced in Thrombocytopenia

Xichun C. Hu

270 Dong An Road, 
Shanghai, CN 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Thrombocytopenia
270 Dong An Road, 
Shanghai, CN 
OverviewLocationsClinical Research

Overview

Xichun Hu practices in Shanghai, China. Hu is rated as an Experienced expert by MediFind in the treatment of Thrombocytopenia. Their top areas of expertise are Breast Cancer, Agranulocytosis, Triple-Negative Breast Cancer, Tissue Biopsy, and Abdominal Wall Surgery.

Their clinical research consists of co-authoring 238 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 4 articles in the study of Thrombocytopenia.

Locations

270 Dong An Road, Shanghai, 200032, China
Other Locations
Chinese Academy Of Medical Sciences And Peking Union Medical College, Beijing, 100730, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Randomized, Controlled, Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2
Randomized, Controlled, Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2
Enrollment Status: Recruiting
Publish Date: January 24, 2024
Intervention Type: Drug
Study Drugs: RC48-ADC, Paclitaxel Injection, Docetaxel Injection, Vinorelbine Tartrate Injection, Capecitabine Tablets
Study Phase: Phase 3
Experimental Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of B002 in the Treatment of HER2-positive Recurrent or Metastatic Breast Cancer.
Experimental Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of B002 in the Treatment of HER2-positive Recurrent or Metastatic Breast Cancer.
Enrollment Status: Completed
Publish Date: March 24, 2023
Intervention Type: Biological
Study Drug: Humanized Anti-HER2 Monoclonal Antibody Compound for Injection
Study Phase: Phase 1
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of hLAG-3 Fusion Protein, EOC202 (Eftilagimod Alpha) Combined With Paclitaxel in Chinese Patients With Metastatic Breast Cancer
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of hLAG-3 Fusion Protein, EOC202 (Eftilagimod Alpha) Combined With Paclitaxel in Chinese Patients With Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: March 31, 2022
Intervention Type: Biological, Drug
Study Drugs: EOC202, Paclitaxel
Study Phase: Phase 1
A Multi-Center, Open Label Phase Ib/II Clinical Study to Evaluate JS001 in Patients With Advanced Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Nasopharyngeal Carcinoma and Head and Neck Squamous Cell Carcinoma
A Multi-Center, Open Label Phase Ib/II Clinical Study to Evaluate JS001 in Patients With Advanced Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Nasopharyngeal Carcinoma and Head and Neck Squamous Cell Carcinoma
Enrollment Status: Unknown
Publish Date: December 13, 2021
Intervention Type: Biological
Study Drug: JS001 Anti-PD-1 Antibody
Study Phase: Phase 1/Phase 2
View 3 Less Clinical Trials

237 Total Publications

Tibremciclib or Placebo Plus Fulvestrant in Hormone Receptor-Positive and ERBB2-Negative Advanced Breast Cancer After Endocrine Therapy: A Randomized Clinical Trial.
Tibremciclib or Placebo Plus Fulvestrant in Hormone Receptor-Positive and ERBB2-Negative Advanced Breast Cancer After Endocrine Therapy: A Randomized Clinical Trial.
Journal: JAMA oncology
Published: July 31, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Hu's expertise for a condition
ConditionClose
    View All 21 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile